Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded
A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe
Eli Lilly has agreed to buy a gene-editing programme for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biot
Bristol-Myers Squibb has decided it wants complete, worldwide control of cardiovascular drug mavacamten, tipped as a future blockbuster, so it has paid $350 million to sho
MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by